<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00290563</url>
  </required_header>
  <id_info>
    <org_study_id>0594-003</org_study_id>
    <secondary_id>MK0594-003</secondary_id>
    <secondary_id>2005_102</secondary_id>
    <nct_id>NCT00290563</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of MK0594 to Treat Overactive Bladder (0594-003)</brief_title>
  <official_title>A Multicenter, Double-Blind, Randomized, Placebo- and Active-Controlled, Parallel-Group, Dose-Ranging Study of MK0594 in Patients With Overactive Bladder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Menlo Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Menlo Therapeutics Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to investigate whether a new drug may offer safe and effective
      treatment for patients with overactive bladder.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 21, 2006</start_date>
  <completion_date type="Actual">September 24, 2007</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in baseline in average daily micturitions as recorded on patient voiding diaries.</measure>
    <time_frame>Duration of Trial</time_frame>
    <description>Change in baseline in average daily micturitions as recorded on patient voiding diaries.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of dry mouth.</measure>
    <time_frame>Duration of Treatment</time_frame>
    <description>The incidence of dry mouth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average daily strong urgency, total incontinence, and Urge UI episodes from voiding diaries.</measure>
    <time_frame>Duration of Treatment</time_frame>
    <description>Average daily strong urgency, total incontinence, and Urge UI episodes from voiding diaries.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment of improvement in UI, perception of urgency, and bother of UI symptoms.</measure>
    <time_frame>Duration of Treatment</time_frame>
    <description>Global assessment of improvement in UI, perception of urgency, and bother of UI</description>
  </secondary_outcome>
  <enrollment type="Actual">557</enrollment>
  <condition>Urinary Incontinence</condition>
  <condition>Overactive Bladder</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK0594</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with predominantly urge incontinence overactive bladder episodes

          -  Patients must meet minimum eligibility requirements (e.g., average number of
             micturitions/day) based on screening diary cards

        Exclusion Criteria:

          -  History of Diabetes insipidus, uncontrolled hyperglycemia or hypercalcemia

          -  Lower urinary tract symptoms associated with benign prostatic hypertrophy

          -  Active or current Urinary Tract Infections (UTIs)

          -  Surgery to correct prolapsed uterus or stress incontinence
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>New Zealand</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 10, 2006</study_first_submitted>
  <study_first_submitted_qc>February 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2006</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

